Liu Yusheng, Zhang Junfeng, Lai Yigui, Wu Chunying, Liu Dongsheng, Liang Rongyao, Chen Gang, Jiang Xuefeng
Comprehensive Laboratory, Yangjiang People's Hospital, Yangjiang, 529500, People's Republic of China.
Department of Traditional Chinese Medicine, Hainan West Central Hospital, Danzhou, 571700, People's Republic of China.
Breast Cancer (Dove Med Press). 2025 May 10;17:385-401. doi: 10.2147/BCTT.S510274. eCollection 2025.
Chaihu-Danggui Tang (CHDGT) has a long history in traditional Chinese medicine (TCM) as an adjuvant therapy for breast cancer (BC), but its precise anti-tumor mechanisms remain unknown. In this study, we used network pharmacology, molecular docking, and experimental validation methods to investigate the core components, key targets, and possible mechanisms through which CHDGT may exert therapeutic effects in BC treatment.
The Traditional Chinese Medicine Systems Pharmacology (TCMSP) was employed to obtain the active ingredient and targets of CHDGT. Meanwhile, the GeneCards databases were used to retrieve pertinent targets for BC. The Venn plot was used to obtain intersection targets. Cytoscape software was used to construct an "CHDGT-active ingredients-targets" network and identify core targets. The common targets after STRING processing were imported into the Metascape database for GO and KEGG pathway enrichment analysis. Molecular docking of key ingredients and core targets of drugs was accomplished using Autodock and PyMol software. The cell and animal experiments confirmed CHDGT efficacy and mechanism in treating BC.
We screened 5 key effector components, 8 core targets, and multiple signaling pathways of CHDGT in treating BC. In vitro, the results of CCK-8 assay showed that CHDGT can dose-dependently inhibits BC cell growth, and at 100 mg L after 48 hours, the cell inhibition rate reached approximately 50%. Further analysis showed that CHDGT can promote apoptosis of BC cell, and regulate the expression levels of apoptosis-related genes, such as Caspase3, p53, and Bcl-2. The animal experiments verified that CHDGT can significantly inhibit the progression of BC, the tumor inhibition rate of CHDGT-H groups was as high as 60.06 ± 4.82%. In addition, H&E staining and blood biochemical analysis suggest that CHDGT exhibits favorable safety.
This study may provide perspectives for the development of anticancer Chinese herbs for the treatment of BC.
柴胡当归汤(CHDGT)在中医中作为乳腺癌(BC)辅助治疗药物有着悠久的历史,但其确切的抗肿瘤机制尚不清楚。在本研究中,我们采用网络药理学、分子对接和实验验证方法,研究CHDGT在BC治疗中发挥治疗作用的核心成分、关键靶点和可能的机制。
运用中药系统药理学数据库(TCMSP)获取CHDGT的活性成分和靶点。同时,使用GeneCards数据库检索BC的相关靶点。采用维恩图获取交集靶点。利用Cytoscape软件构建“CHDGT-活性成分-靶点”网络并识别核心靶点。将STRING处理后的共同靶点导入Metascape数据库进行基因本体(GO)和京都基因与基因组百科全书(KEGG)通路富集分析。使用Autodock和PyMol软件完成药物关键成分与核心靶点的分子对接。细胞和动物实验证实了CHDGT治疗BC的疗效和机制。
我们筛选出CHDGT治疗BC的5个关键效应成分、8个核心靶点和多个信号通路。体外实验中,CCK-8检测结果显示CHDGT能剂量依赖性地抑制BC细胞生长,48小时后100mg/L时细胞抑制率达到约50%。进一步分析表明,CHDGT能促进BC细胞凋亡,并调节凋亡相关基因如Caspase3、p53和Bcl-2的表达水平。动物实验证实CHDGT能显著抑制BC进展,CHDGT-H组的肿瘤抑制率高达60.06±4.82%。此外,苏木精-伊红(H&E)染色和血液生化分析表明CHDGT具有良好的安全性。
本研究可为开发治疗BC的抗癌中药提供思路。